Host: |
Rabbit |
Applications: |
WB/IF |
Reactivity: |
Human/Mouse/Rat |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit polyclonal antibody anti-MARCKS (1-100) is suitable for use in Western Blot and Immunofluorescence research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.01% Thimerosal, 50% Glycerol, pH7.3. |
Purification: |
Affinity purification |
Dilution Range: |
WB 1:500-1:2000IF/ICC 1:50-1:200 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
MARCKS |
Gene ID: |
4082 |
Uniprot ID: |
MARCS_HUMAN |
Immunogen Region: |
1-100 |
Immunogen: |
A synthetic peptide corresponding to a sequence within amino acids 1-100 of human MARCKS (NP_002347.5). |
Immunogen Sequence: |
MGAQFSKTAAKGEAAAERPG EAAVASSPSKANGQENGHVK VNGDASPAAAESGAKEELQA NGSAPAADKEEPAAAGSGAA SPSAAEKGEPAAAAAPEAGA |
Post Translational Modifications | Phosphorylation by PKC displaces MARCKS from the membrane. It also inhibits the F-actin cross-linking activity. |
Function | MARCKS is the most prominent cellular substrate for protein kinase C. This protein binds calmodulin, actin, and synapsin. MARCKS is a filamentous (F) actin cross-linking protein. |
Protein Name | Myristoylated Alanine-Rich C-Kinase SubstrateMarcksProtein Kinase C Substrate - 80 Kda Protein - Light Chain80k-L ProteinPkcsl |
Database Links | Reactome: R-HSA-399997 |
Cellular Localisation | CytoplasmCytoskeletonMembraneLipid-Anchor |
Alternative Antibody Names | Anti-Myristoylated Alanine-Rich C-Kinase Substrate antibodyAnti-Marcks antibodyAnti-Protein Kinase C Substrate - 80 Kda Protein - Light Chain antibodyAnti-80k-L Protein antibodyAnti-Pkcsl antibodyAnti-MARCKS antibodyAnti-MACS antibodyAnti-PRKCSL antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance